Synthesis, Biological Evaluation and Docking Studies of Chalcone and Flavone Analogs as Antioxidants and Acetylcholinesterase Inhibitors by Díaz-Rubio, Laura et al.
applied  
sciences
Article
Synthesis, Biological Evaluation and Docking Studies
of Chalcone and Flavone Analogs as Antioxidants and
Acetylcholinesterase Inhibitors
Laura Díaz-Rubio 1 , Rufina Hernández-Martínez 2 , Arturo Estolano-Cobián 1 ,
Daniel Chávez-Velasco 3 , Ricardo Salazar-Aranda 4, Noemí Waksman de Torres 4,
Ignacio A. Rivero 3, Víctor García-González 5 , Marco A. Ramos 1,* and
Iván Córdova-Guerrero 1,*
1 Facultad de Ciencias Químicas e Ingeniería, Universidad Autónoma de Baja California,
Tijuana, B.C. 22390, México; ldiaz26@uabc.edu.mx (L.D.-R.); arturo.estolano@uabc.edu.mx (A.E.-C.)
2 Departamento de Microbiología, Centro de Investigación Científica y de Educación Superior de Ensenada,
Ensenada, B.C. 22860, México; ruhernan@cicese.mx
3 Centro de Graduados e Investigación en Química, Tecnológico Nacional de México/Instituto Tecnológico de
Tijuana, Tijuana, B.C. 22510, México; dchavez@tectijuana.mx (D.C.-V.); irivero@tectijuana.mx (I.A.R.)
4 Departamento de Química Analítica, Facultad de Medicina, Universidad Autónoma de Nuevo León,
San Nicolas de los Garza, Monterrey 64460, México; salazar121212@yahoo.com (R.S.-A.);
nwaksman@gmail.com (N.W.d.T.)
5 Facultad de Medicina, Universidad Autónoma de Baja California, Mexicali, B.C. 21000, México;
vgarcia62@uabc.edu.mx
* Correspondence: mramos@uabc.edu.mx (M.A.R.); icordova@uabc.edu.mx (I.C.-G.);
Tel.: +52-664-120-7741 (I.C.-G.)
Received: 27 December 2018; Accepted: 21 January 2019; Published: 26 January 2019


Abstract: Several oxidative processes are related to a wide range of human chronic and degenerative
diseases, like Alzheimer’s disease, which also has been related to cholinergic processes. Therefore,
search for new or improved antioxidant molecules with acetylcholinesterase activity is essential
to offer alternative chemotherapeutic agents to support current drug therapies. A series of
chalcone (2a–2k) and flavone (3a–3k) analogs were synthesized, characterized, and evaluated as
acetylcholinesterase (AChE) inhibitors, and antioxidant agents using 1,1-diphenyl-2-picrylhydrazyl
(DPPH•), 2-2′-azino-bis-(3-ethylbenzothiazoline-6-sulfonate) (ABTS•), and β-carotene/linoleic acid
bleaching assay. Compounds more active were 3j and 2k in DPPH with EC50 of 1 × 10−8 and
5.4 × 10−3 µg/mL, respectively; 2g and 3i in ABTS (1.14 × 10−2 and 1.9 × 10−3 µg/mL); 2e, 2f,
3f, 2j, and 3j exceeded the α-tocopherol control in the β-carotene assay (98–99% of antioxidant
activity). At acetylcholinesterase inhibition assay, flavones were more active than chalcones; the best
results were compounds 2d and 3d (IC50 21.5 and 26.8 µg/mL, respectively), suggesting that the
presence of the nitro group enhances the inhibitory activity. The docking of these two structures
were made to understand their interactions with the AChE receptor. Although further in vivo testing
must be performed, our results represent an important step towards the identification of improved
antioxidants and acetylcholinesterase inhibitors.
Keywords: chalcone; flavone; antioxidant activities; DPPH; acetylcholinesterase; docking
1. Introduction
Collectively, radical and non-radical species formed by the partial reduction of oxygen are known
as reactive oxygen species (ROS) [1]. When ROS overcame the cellular antioxidant defense system,
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whether through an increase in ROS levels or a decrease in the cellular antioxidant capacity, oxidative
stress occurs [2], which disturbs cellular metabolism, damages cellular constituents, and triggers the
activation of specific signaling pathways [3]. The pathogenesis of several chronic and degenerative
human diseases, including cardiovascular, neurodegenerative, and cancerous ones, has been linked to
a cellular condition exhibiting oxidative stress [4,5]. To counteract this stressful condition, the human
body has several mechanisms and produces a broad variety of antioxidants [6], which together quench
ROS activities and reduce cellular damage [7].
Oxidative stress plays a crucial role in the etiology and pathogenesis of neurodegenerative
diseases, like Alzheimer [8]. Alzheimer’s disease (AD) is globally the most common cause of
dementia in adults above 60 years [9]; ageing lowers the antioxidant systems activity, leading to free
radical progressive accumulation, triggering lipid peroxidation mechanisms and structural damage
to proteins and DNA [10], which leads to brain tissue damage. Its progression is associated to
biochemical changes, like cholinergic deficit, neuronal metabolic damage derived from the glutamate
excitotoxicity, and oxidative stress [11]. Acetylcholinesterase inhibitors (AChEI) are actually the best
available pharmacotherapy for Alzheimer’s disease symptoms treatment, increasing the levels of the
acetylcholine neurotransmitter during the cerebral cortex synapses [12].
Flavonoids comprise a large family of plant-derived structurally-related polyphenolic compounds
that are classified as anthocyanidins, flavonols, chalcones, aurones, flavanones, isoflavones, flavans,
flavanonols, flavanols, and flavones [13]. Flavonoids have been found to display biological activities,
such as anti-inflammatory [14], hepatoprotective [15], antiulcer [16], enzyme inhibitors, such as
cyclooxygenase [17], xanthine oxidase [18], lipoxygenase [19], phosphodiesterase [20], as well as
antiviral [21], cardioprotective [22], anticancer [23], and antioxidant [24] functions.
Pharmacological effects of flavonoids are related to their antioxidant activity, as they are powerful
antioxidants against free radicals and ROS [12]. Structurally, the free radical scavenging capacity is
primarily attributed to high reactivity of their hydroxyl substituents that participate in the reaction [25].
In this context, we report the chemical synthesis of chalcone and flavone analogs with different
substituents on the respective B ring (Figure 1). In addition to the mandatory molecule characterization,
their antioxidant and AChE inhibition activity was evaluated by in vitro testing, to get preliminary
insights regarding the structure-activity relationship, allowing for us to further develop the continuous
search for new therapeutic agents.
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2. Materials and Methods
2.1. General Information
All commercial reagents and solvents were used as received and did not require any purification
before use. Melting points were taken on a Mel-Temp melting point apparatus (Thermo Scientific).
UV spectra were recorded on UV-VIS spectrophotometer model type Genesys 20 and expressed
in nm. FT-IR spectroscopic studies were carried out on a FT-IR spectrophotometer Nicolet is5
(Thermo Scientific). NMR spectra were recorded on a Bruker Avance III spectrometer 400 MHz.
The chemical shifts (δ) are presented with tetramethylsilane (TMS) (δ: 0.00) as the internal standard.
Gas chromatography–Mass spectrometry data were recorded on a Thermo Scientific TRACE 1310 (GC)
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and Thermo Scientific single quadrupole ISQ LT (MS), with a column model TG-SQC (30 m × 0.25 mm
inner diameter, 0.25 µm film thickness). The detector temperature was 240 ◦C, the injector temperature
was 250 ◦C, and transfer-line temperature was 250 ◦C; oven temperature started at 120 ◦C for 1 min,
increased at a 40 ◦C/min rate until 280 ◦C, with a hold time of 10 min. Helium was employed as
carrier gas, at 1 mL/min flow with split ratio 1:20. Column chromatography purifications were carried
out on Silica Gel 60Å (Sigma-Aldrich, 230–400 mesh, Sigma-Aldrich, Milwaukee, WI, USA). The purity
of compounds was checked by thin-layer chromatography (TLC) carried out on aluminum backed
silica plates by Merck (Kenilworth, NJ, USA) and plates were revealed using a UV 254 nm light.
2.2. Synthesis of Chalcone Derivatives
To a mixture of 2-hydroxyacetophenone (1 Eq) and the appropriate benzaldehyde (1a–1k) (1 Eq)
in ethanol/water (8:2) (10 mL), was added dropwise aqueous NaOH 50% (4 mL) at 0 ◦C. The reaction
was stirred at room temperature till completion of reaction (monitored by TLC). The reaction solvent
was completely evaporated to redissolve the crude in water and neutralize with a 10% HCl solution.
The precipitate was filtered, washed with cold water, dried, and purified by column chromatography,
employing eluent mixtures of n-hexane/ethyl acetate and dichloromethane/ethyl acetate in different
proportions; some products were purified by recrystallization with a methanol/H2O (1:2) mixture.
All of the structures were confirmed by mass and NMR spectra as discussed below.
(E)-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one (2a): White solid (yield 46%). C15H12O2.
Mp = 58–60 ◦C. IR (ATR diamond, cm−1) = 3358 (O-H), 3031 (C-H), 1683 (C=O) cm−1. 1H NMR
(400 MHz, CDCl3) δ: 12.79 (s, 1H, OH), 7.93 (d, J = 15.3 Hz, 1H, H7), 7.92 (d, J = 8.1 Hz, 1H, H2′), 7.67
(d, J = 15.2 Hz, 1H, H8), 7.50-7.37 (m, 6H, H2, H3, H4, H5, H6, H4′), 7.06 (d, J = 8.6 Hz, 1H, H5′), 6.95
(d, J = 7.3 Hz, 1H, H3′). 13C NMR (100 MHz, CDCl3) δ: 193.8 (s, C9), 163.7 (s, C6′), 145.5 (d, C7), 136.5
(d, C4′), 134.7 (s, C1), 131.0 (d, C2′), 129.7 (d, C3, C5), 129.1 (d, C2, C6), 128.7 (d, C4), 126.2 (d, C3′),
120.3 (s, C1′), 118.9 (d, C8), 118.7 (d, C5′). GC-MS m/z (rel. int.) = 224.15 [M]+ (11), 223.16 (12), 147.08
(17), 120.06 (49), 104.11 (54), 92.05 (100), 77.08 (54).
(E)-1,3-bis(2-hydroxyphenyl)prop-2-en-1-one (2b): Yellow crystals (yield 41%). C15H12O3.
Mp = 137 ◦C. IR (ATR diamond, cm−1) = 3267 (O-H), 3033 (C-H), 1683 (C=O), 1150 (C-O) cm−1.
1H NMR (400 MHz, CDCl3) δ: 12.63 (s, 1H, OH), 10.36 (s, 1H, OH), 8.21 (d, J = 15.3 Hz, 1H, H7), 8.21
(dd, J1 = 7.9, J2 = 1.4 Hz, 1H, H2′), 8.00 (d, J = 15.6 Hz, 1H, H8), 7.92 (dd, J1 = 7.8, J2 = 1.0 Hz, 1H, H6),
7.58 (ddd, J1 = 8.2, J2 = 8.6, J3 = 1.4 Hz, 1H, H4′), 7.33 (ddd, J1 = 8.2, J2 = 8.4, J3 = 1.3 Hz, 1H, H4), 7.03
(ddd, J1 = 7.1 Hz, 1H, H5), 6.99 (dd, J1 = 8.3 Hz, 1H, H5′), 6.92 (dd, J1 = 7.5 Hz, 1H, H3′), 6.02 (ddd,
J1 = 8.3 Hz, 1H, H3). 13C NMR (100 MHz, CDCl3) δ: 193.8 (s, C9), 157.4 (s, C2), 140.3 (d, C7), 136.0 (d,
C4′), 132.4 (d, C2′), 130.5 (d, C4), 128.9 (d, C6), 121.1 (s, C1), 120.7 (d, C3′), 120.2 (s, C1′), 119.4 (d, C8),
119.0 (d, C5), 117.7 (d, C5′), 116.2 (d, C3). GC-MS m/z (rel. int.) = 240.18 [M]+ (1), 222.18 (8), 147.11 (2),
121.09 (28), 92.1 (100), 63.07 (73), 39.06 (56).
(E)-3-(4-hydroxy-3-methoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (2c): Orange crystals (yield
42%). C16H14O4. Mp = 120 ◦C. IR (ATR diamond, cm−1) = 3377 (O-H), 3009 (C-H), 2965 (C-H), 1682
(C=O) cm−1. 1H NMR (400 MHz, CDCl3) δ: 12.90 (s, 1H, OH), 7.94 (dd, J1 = 8.1, J2 = 1.6 Hz, 1H, H2′),
7.93 (d, J = 15.2 Hz, 1H, H7), 7.52 (d, J = 15.6 Hz, 1H, H8), 7.51 (ddd, J1 = 8.4, J2 = 8.4, J3 = 1.6 Hz, 1H,
H4′), 7.14-6.93 (m, 5H, H2, H3, H6, H3′, H5′), 3.97 (s, 3H, H10).13C NMR (100 MHz, CDCl3) δ: 193.6 (s,
C9), 163.5 (s, C6′), 148.7 (s, C3), 146.9 (s, C4), 145.8 (d, C7), 136.1 (d, C4′), 129.5 (d, C2′), 127.4 (s, C1),
123.7 (d, C6), 121.6 (d, C3′), 120.9 (s, C1′), 118.7 (d, C8), 118.1 (d, C5′), 117.6 (d, C5), 110.3 (d, C2), 56.1
(q, C10). GC-MS m/z (rel. int.) = 270.25 [M]+ (4), 150.19 (28), 135.16 (29), 121.15 (16), 120.15 (26), 107.16
(33), 92.11 (100), 77.15 (68), 64.12 (68).
(E)-3-(2-hydroxy-5-nitrophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (2d): Yellow powder (yield 46%).
C15H11NO5. Mp = 120 ◦C. IR (ATR diamond, cm−1) = 3565 (O-H), 3068 (C-H), 1656 (C=O), 1578 (N-O),
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1337 (N-O), cm−1. 1H NMR (400 MHz, CDCl3) δ: 12.44 (s, 1H, OH), 8.81 (d, J = 2.7 Hz, 1H, H6), 8.28
(dd, J1 = 8.4, J2 = 1.3 Hz, 1H, H4), 8.196 (d, J = 15.5 Hz, 1H, H7), 8.192 (dd, J1 = 9.2, J2 = 2.8 Hz, 1H, H2′),
8.10 (d, J = 15.7 Hz, 1H, H8), 7.60 (dd, J1 = 7.4, J2 = 1.4 Hz, 1H, H4′), 7.13 (d, J = 9.1 Hz, 1H, H3′), 7.04
(dd, J1 = 7.8, J2 = 1.0 Hz, 1H, H5′), 7.03 (d, J = 7.8 Hz, 1H, H3). 13C NMR (100 MHz, CDCl3) δ: 193.5 (s,
C9), 162.8 (s, C2), 161.8 (s, C6′), 140.0 (s, C5), 137.4 (d, C7), 136.2 (d, C4′), 130.9 (d, C2′), 127.3 (d, C4,
C6), 124.5 (d, C3′), 123.2 (s, C1′), 121.7 (d, C8), 119.0 (d, C5′), 117.6 (s, C1), 116.6 (d, C3). GC-MS m/z
(rel. int.) = 285.15 [M]+ (1), 253.64 (1), 220.22 (4), 191.54 (3), 171.27 (6), 149.28 (6), 137.01 (16), 117.17 (18),
84.18 (51), 73.10 (32), 69.20 (41), 63.11 (49), 61.14 (41), 30.16 (100).
(E)-1-(2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (2e): Yellow crystals (yield 40%).
C16H14O3. Mp = 76–78 ◦C. IR (ATR diamond, cm−1) = 3082 (C-H), 2963 (C-H), 1685 (C=O), 1255
(C-O) cm−1. 1H NMR (400 MHz, CDCl3) δ: 12.91 (s, 1H, OH), 7.919 (dd, J1 = 8.0, J2 = 1.7 Hz, 1H, H2′),
7.911 (d, J = 15.0 Hz, 1H, H7), 7.62 (dd, J1 = 8.8, J2 = 1.7 Hz, 1H, H2), 7.60 (dd, J1 = 8.5, J2 = 1.7 Hz, 1H,
H6), 7.54 (d, J = 15.0 Hz, 1H, H8), 7.49 (ddd, J1 = 8.6, J2 = 8.5, J3 = 1.5 Hz, 1H, H4′), 7.02 (dd, J1 = 8.4,
J2 = 1.0 Hz, 1H, H5′), 6.95 (dd, J1 = 8.8, J2 = 2.0 Hz, 2H, H3, H5), 6.94 (ddd, J1 = 9.6, J2 = 10.9, J3 = 1.2
Hz, 1H, H3′), 3.85 (s, 3H, H10). 13C NMR (100 MHz, CDCl3) δ: 193.8 (s, C9), 163.7 (s, C6′), 162.1 (s, C4),
145.4 (d, C7), 136. 2 (s, C4′),130.6 (d, C2, C6), 129.6 (d, C2′), 127.5 (s, C1), 120.2 (s, C1′), 118.8 (d, C5′),
118.7 (d, C3′), 117.7 (d, C8), 114.6 (d, C3, C5), 55.5 (q, C10). GC-MS m/z (rel. int.) = 254.19 [M]+ (17),
253.20 (12), 134.12 (100), 121.11 (34), 119.12 (40), 92.07 (79), 65.08 (84), 63.07 (90).
(E)-1-(2-hydroxyphenyl)-3-(3-methoxyphenyl)prop-2-en-1-one (2f): Orangish yellow crystals (yield
40%). C16H14O3. Mp = 86–90 ◦C. IR (ATR diamond, cm−1) = 3081 (C-H), 2918 (C-H), 1636 (C=O), 1253
(C-O) cm−1. 1H NMR (400 MHz, CDCl3) δ: 12.77 (s, 1H, OH), 7.91 (dd, J1 = 8.0, J2 = 1.6 Hz, 1H, H2′),
7.89 (d, J = 15.8 Hz, 1H, H7), 7.63 (d, J = 15.4 Hz, 1H, H8), 7.51 (ddd, J1 = 8.5, J2 = 8.6, J3 = 1.6 Hz, 1H,
H4′), 7.36 (dd, J1 = 7.8 Hz, 1H, H6), 7.26 (dd, J1 = 7.6 Hz, 1H, H4), 7.16 (dd, J1 = 2.2, J2 = 1.8 Hz, 1H,
H2), 7.03 (dd, J1 = 8.4, J2 = 1.0 Hz, 1H, H5′), 6.99 (ddd, J1 = 8.1, J2 = 8.2, J3 = 1.0 Hz, 1H, H5), 6.96 (ddd,
J1 = 8.1, J2 = 8.2, J3 = 1.1 Hz, 1H, H3′), 3.85 (s, 3H, H10). 13C NMR (100 MHz, CDCl3) δ: 193.85 (s, C9),
163.7 (s, C6′), 160.1 (s, C3), 145.5 (d, C7), 136.5 (d, C4′), 136.13 (s, C1), 130.1 (d, C2′), 129.8 (d, C5), 121.4
(d, C3′), 120.6 (s, C1′), 120.1 (d, C6), 118.9 (d, C8), 118.7 (d, C5′), 116.7 (d, C4), 113.9 (d, C2), 55.5 (q,
C10). GC-MS m/z (rel. int.) = 254.15 [M]+ (11), 253.18 (8), 165.12 (3), 147.08 (27), 134.10 (17), 121.05
(52), 102.06 (18), 92.05 (36), 89.06 (41), 65.04 (100).
(E)-3-(3,4-dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (2g): yellow crystals (yield 57%).
C17H16O4. Mp = 88–90 ◦C. IR (ATR diamond, cm−1) = 3079 (C-H), 1694 (C=O), 1142 (C-O) cm−1. 1H
NMR (400 MHz, CDCl3) δ: 12.90 (s, 1H, OH), 7.94 (dd, J1 = 8.1, J2 = 1.8 Hz, 1H, H2′), 7.89 (d, J = 15.4,
1H, H7), 7.53 (d, J = 15.3 Hz, 1H, H8), 7.50 (ddd, J1 = 8.4, J2 = 8.5, J3 = 1.3, 1H, H4′), 7.27 (dd, J1 = 8.3, J2
= 2.0 Hz, 1H, H6), 7.17 (d, 1H, H2), 7.03 (ddd, J1 = 8.3, J2 = 8.3, J3 = 1.0 Hz, 1H, H3′), 6.95 (dd, J1 = 8.1,
J2 = 1.0 Hz, 1H, H5′), 6.91 (d, 1H, H5), 3.96 (s, 3H, H10), 3.93 (s, 3H, H11). 13C NMR (100 MHz, CDCl3)
δ: 193.7 (s, C9), 163.6 (s, C6′), 151.9 (s, C3), 149.4 (s, C4), 145.7 (d, C7), 136.2 (d, H4′), 129.6 (d, C2′),
127.7 (s, C1), 123.6 (d, C6), 121.6 (d, C3′), 120.2 (s, C1′), 118.8 (d, C8), 117.9 (d, C5′), 111.3 (d, C5), 110.5
(d, C2), 56.1 (q, C10, C11). GC-MS m/z (rel. int.) = 284.20 [M]+ (8), 165.16 (4), 164.16 (33), 151.15 (25),
121.13 (24), 103.11 (27), 92.06 (69), 77.08 (100).
(E)-3-(4-chlorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (2h): yellow crystals (yield 97%).
C15H11ClO2. Mp = 70–73 ◦C. IR (ATR diamond, cm−1) = 3065 (C-H), 1641 (C=O), 748 (C-Cl) cm−1.
1H NMR (400 MHz, CDCl3) δ: 12.72 (s, 1H, OH), 7.90 (dd, J1 = 8.0, J2 = 1.6 Hz, 1H, H2′), 7.86 (d,
J = 15.4 Hz, 1H, H7), 7.62 (d, J = 15.4 Hz, 1H, H8), 7.59 (d, 2H, H2, H6), 7.51 (ddd, J1 = 8.8, J2 = 8.6,
J3 = 1.5 Hz, 1H, H4′), 7.41 (d, 2H, H3, H5), 7.03 (dd, J1 = 8.4, J2 = 1.0 Hz, 1H, H5′), 6.95 (ddd, J1 = 8.1, J2
= 8.0, J3 = 1.1 Hz, 1H, H3′). 13C NMR (100 MHz, CDCl3) δ: 193.5 (s, C9), 163.7 (s, C6′), 144.0 (d, C7),
137.0 (d, C4′), 136.6 (s, C1), 133.2 (s, C4), 129.9 (d, C2, C6), 129.7 (d, C2′), 129.4 (d, C3, C5), 120.7 (d,
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C3′), 120, 0 (s, C1′), 119.0 (d, C8), 118.8 (d, C5′). GC-MS m/z (rel. int.) = 258.21 [M]+ (4), 224.12 (5),
223.18 (26), 165.18 (7), 147.11 (20), 121.13 (32), 101.10 (39), 93.13 (26), 65.12 (100).
(E)-3-(4-(dimethylamino)phenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one (2i): purple red crystals (yield
51%). C17H17NO2. Mp = 163–165 ◦C. IR (ATR diamond, cm−1) = 3064 (C-H), 1661 (C=O), 1276 (C-N)
cm−1. 1H NMR (400 MHz, CDCl3) δ: 13.18 (s, 1H, OH), 7.919 (d, J = 14.9 Hz, 1H, H7), 7.915 (dd,
J1 = 8.3, J2 = 1.8 Hz, 1H, H2′), 7.56 (dd, J1 = 8.8, J2 = 1.8 Hz, 2H, H2, H6), 7.46 (ddd, J1 = 8.5, J2 = 8.2,
J3 = 1.6 Hz, 1H, H4′), 7.45 (d, J = 15.1 Hz, 1H, H8), 7.00 (dd, J1 = 8.3, J2 = 1.0 Hz, 1H, H5′), 6.92 (ddd,
J1 = 8.2, J2 = 8.0, J3 = 1.2 Hz, 1H, H3′), 6.68 (dd, J1 = 8.9, J2 = 2.8 Hz, 2H, H3, H5), 3.03 (s, 6H, H10). 13C
NMR (100 MHz, CDCl3) δ: 193.6 (s, C9), 163.6 (s, C6′), 152.4 (s, C4), 146.6 (d, C7), 135.7 (d, C4′), 130.9
(d, C2, C6), 129.4 (d, C2′), 122.4 (s, C1), 120.5 (d, C3′), 118.6 (s, C1′), 118.5 (d, C8), 114.4 (d, C5′), 111.9 (d,
C3, C5), 40.1 (q, C10). GC-MS m/z (rel. int.) = 267.11 [M]+ (6), 266.11 (3), 220.13 (9), 165.16 (8), 152.16
(3), 104.05 (11), 92.09 (21), 89.06 (39), 76.07 (100).
(E)-3-(anthracen-9-yl)-1-(2-hydroxyphenyl)prop-2-en-1-one (2j): orange crystals (yield 45%). C23H16O2.
Mp = 148-150 ◦C. IR (ATR diamond, cm−1) = 3046 (C-H), 1633 (C=O), 1157 (C-O) cm−1. 1H NMR (400
MHz, CDCl3) δ: 12.85 (s, 1H, OH), 8.89 (d, J = 15.6 Hz, 1H, H15), 8.45 (s, 1H, H8), 8.27 (dd, J1 = 9.4, J2 =
2.9 Hz, 2H, H3, H13), 8.02 (dd, J1 = 9.6, J2 = 2.9 Hz, 2H, H6, H10), 7.81 (dd, J1 = 9.6, J2 = 1.4 Hz, 1H,
H2′), 7.65 (d, J = 15.6 Hz, 1H, H16), 7.53-7.46 (m, 4H, H4, H5, H11, H12), 7.53 (ddd, J1 = 8.3, J2 = 8.3, J3
= 1.7 Hz, H4′) 7.08 (dd, J1 = 8.4, J2 = 1.0 Hz, 1H, H5′), 6.89 (ddd, J1 = 8.1, J2 = 8.1, J3 = 1.1 Hz, 1H, H3′).
13C NMR (100 MHz, CDCl3) δ: 193.3 (s, C17), 163.9 (s, C6′), 142.7 (d, C15), 136.7 (d, C4′), 131.4 (s, C1),
130.0 (s, C7, C9), 129.8 (d, C6, C10, C2′), 129.5 (d, C3, C13), 129.1 (s, C2, C14), 128.9 (d, C4, C12), 126.7
(d, C5, C11), 125.6 (s, C3′), 120.1 (d, C8, C4′), 119.1 (d, C16), 118.8 (d, C5′). GC-MS m/z (rel. int.) =
324.22 [M]+(27), 281.96 (5), 268.48 (5), 203.17 (17), 202.14 (35), 200.18 (11), 178.27 (12), 124.79 (15), 121.01
(90), 93.12 (36), 65.05 (100).
(E)-3-(furan-2-yl)-1-(2-hydroxyphenyl)prop-2-en-1-one (2k): yellow crystals (yield 84%). C13H10O3.
Mp = 90–92 ◦C. IR (ATR diamond, cm−1) = 3128-3150 (C-H), 1669 (C=C), 1636 (C=O), 1158 (C-O) cm−1.
1H NMR (400 MHz, CDCl3) δ: 12.86 (s, 1H, OH), 7.91 (dd, J1 = 8.0, J2 = 1.4 Hz, 1H, H2′), 7.69 (d, J= 15.1
Hz, 1H, H5), 7.56 (d, J = 15.1 Hz, 1H, H6), 7.55 (dd, J1 = 3.4, J2 = 1.3 Hz, 1H, H4), 7.49 (ddd, J1 = 8.5,
J2 = 8.5, J3 = 1.5 Hz, 1H, H4′), 6.94 (ddd, J1 = 8.1, J2 = 8.1, J3 = 1.0 Hz, 1H, H3′), 6.76 (d, 1H, H2). 13C
NMR (100 MHz, CDCl3) δ: 193.4 (s, C7), 163.7 (s, C6′), 151.6 (s, C1), 145.5 (d, C4), 136.4 (d, C4′), 131.2
(d, C2′), 129.7 (d, C6), 120.2 (d, C3′), 118.9 (s, C1′), 118.6 (d, C5), 117.8 (d, C5′), 117.1 (d, C2), 113.0 (d,
C3). GC-MS m/z (rel. int.) = 214.20 [M]+ (6), 157.12 (3), 131.17 (3), 128.16 (3), 121.12 (23), 94.13 (18),
92.11 (13), 77.10 (9), 65.11 (74), 39.09 (100).
2.3. Synthesis of Flavone Derivatives
To a solution of the corresponding 2-hydroxychalcone (2a–2k) (1 Eq) and I2 (1 Eq), was added
DMSO (5 mL) and the reaction mixture was heated in an oil bath at 130 ◦C until the completion of
reaction (monitored by TLC). After cooling, the reaction mixture was diluted with water and the iodine
was removed by washing with a saturated solution of sodium thiosulfate. The products (3a–3k) were
then extracted with ethyl acetate and purified by column chromatography, employing eluent mixtures
of n-hexane/ethyl acetate, dichloromethane/ethyl acetate, and ethyl acetate/methanol in different
proportions; some products were purified by recrystallization with a methanol/H2O (1:2) mixture.
2-phenyl-4H-chromen-4-one (3a): white crystals (yield 61%). C15H10O2. Mp = 85–87 ◦C. IR (ATR
diamond, cm−1) = 3072 (C-H), 1639 (C=O), 1030 (C-O) cm−1. 1H NMR (400 MHz, CDCl3) δ: 8.25 (dd,
J1 = 7.9, J2 = 1.5 Hz, 1H, H5), 7.94 (dd, J1 = 9.6, J2 = 1.7 Hz, 2H, H2′, H6′), 7.72 (ddd, J1 = 8.5, J2 = 8.6, J3
= 1.6 Hz, 1H, H7), 7.58-7.50 (m, 4H, H6, H8, H3′, H5′), 7.44 (ddd, J1 = 8.0, J2 = 8.0, J3 = 1.0 Hz, 1H, H4′),
6.82 (s, 1H, H3). 13C NMR (100 MHz, CDCl3) δ: 178.5 (s, C4), 163.5 (s, C2), 156.4 (s, C9), 133.8 (d, C7),
131.9 (s, C1′), 131.7 (d, C3′), 129.1 (d, C5′), 126.4 (d, C4′), 125.8 (d, C5, C2′, C6′), 125.3 (s, C10), 124.1 (d,
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C6), 118.2 (d, C8), 107.7 (d, C3). GC-MS m/z (rel. int.) = 222.12 [M]+ (19), 221.13 (5), 194.11 (14), 165.11
(7), 120.04 (48), 102.06 (28), 97.07 (15), 92.05 (100).
2-(2-hydroxyphenyl)-4H-chromen-4-one (3b): Pale yellow powder (yield 60%). C15H10O3. Mp =
254–256 ◦C. IR (ATR diamond, cm−1) = 3141 (O-H), 3098 (C-H), 1638 (C=O), 1051 (C-O) cm−1. 1H
NMR (400 MHz, CDCl3) δ: 11.02 (s, 1H, OH), 8.17 (dd, 1H, H5), 8.05 (ddd, J1 = 8.6, J2 = 8.6, J3 = 1.1 Hz,
1H, H7), 7.843 (ddd, J1 = 7.8, J2 = 8.0, J3 = 1.0 Hz, 1H, H6), 7.845 (dd, J1 = 8.4, J2 = 1.4 Hz, 1H, H8), 7.80
(ddd, J1 = 8.0, J2 = 8.0, J3 = 1.4 Hz, 1H, H4′), 7.70 (dd, J1 = 8.6, J2 = 2.3 Hz, 1H, H6′), 7.51 (ddd, J1 = 7.9,
J2 = 8.0, J3 = 1.9 Hz, 1H, H5′), 7.12 (s, 1H, H3), 6.92 (dd, 1H, H3′). 13C NMR (100 MHz, CDCl3) δ: 177.0
(s, C4), 159.1 (s, C2), 156.7 (s, C9), 156.3 (s, C2′), 140.6 (d, C7), 136.2 (d, C4′), 134.1 (d, C6′), 125.2 (d,
C5), 124.64 (s, C10), 124.61 (d, C6), 123.0 (d, C5′), 120.3 (s, C1′), 119.5 (d, C3′), 118.5 (d, C8), 111.4 (s,
C3). GC-MS m/z (rel. int.) = 238.23 [M]+ (10), 210.20 (2), 152.27 (3), 121.15 (17), 120.14 (10), 118.16 (12),
92.14 (61), 90.16 (30), 76.15 (21), 64.14 (59), 63.13 (100).
2-(4-hydroxy-3-methoxyphenyl)-4H-chromen-4-one (3c): Yellow powder (yield 40%). C16H12O4. Mp
= 198–200 ◦C. IR (ATR diamond, cm−1) = 3295 (O-H), 3092 (C-H), 2935 (C-H), 1624 (C=O) cm−1. 1H
NMR (400 MHz, CDCl3) δ: 8.12 (dd, J1 = 8.0, J2 = 1.6 Hz, 1H, H5), 8.03 (dd, J2 = 2 Hz, 1H, H8), 7.82
(ddd, J1 = 8.8, J2 = 8.4, J3 = 1.6 Hz, 1H, H7), 7.74 (ddd, J1 = 8.4, J2 = 8.4, J3 = 1 Hz, 1H, H6), 7.59 (dd,
J2 = 2 Hz, 1H, H6′), 7.50 (dd, J1 = 8.8, J2 = 1.2 Hz, 1H, H2′), 6.98 (d, 1H, H3′), 6.84 (s, 1H, H3), 4.01 (s,
3H, H11). 13C NMR (100 MHz, CDCl3) δ: 179.5 (s, C4), 163.9 (s, C2), 157.4 (s, C9), 151.5 (s, C4′), 148.3 (s,
C5′), 135.3 (d, C7), 130.4 (d, C5), 126.5 (s, C10), 126.0 (d, C6), 125.4 (s, C1′), 124.6 (d, C2′), 119.4 (d, C3′),
110.4 (d, C8), 106.8 (d, C6′), 83.7 (d, C3), 57.0 (q, C11). GC-MS m/z (rel. int.) = 268.24 [M]+ (20), 197.16
(8), 148.18 (16), 121.13 (27), 105.14 (47), 92.12 (95), 63.13 (100).
2-(2-hydroxy-5-nitrophenyl)-4H-chromen-4-one (3d): Pale yellow powder (yield 58%). C15H9NO5.
Mp = 268–270 ◦C. IR (ATR diamond, cm−1) = 3298 (O-H), 3024 (C-H), 1652 (C=O), 1342 (N-O) cm−1.
GC-MS m/z (rel. int.) = 282.23 [M]+ (3), 281.20 (10), 235.18 (3), 179.25 (7), 150.19 (10), 104.12 (9), 92.15
(8), 30.09 (100).
2-(4-methoxyphenyl)-4H-chromen-4-one (3e): white powder (yield 50%). C16H12O3. Mp = 158–160 ◦C.
IR (ATR diamond, cm−1) = 3051 (C-H), 2920 (C-H), 1644 (C=O), 1024 (C-O) cm−1. 1H NMR (400 MHz,
CDCl3) δ: 8.22 (dd, J1 = 7.9, J2 = 1.5 Hz, 1H, H5), 7.87 (dd, J1 = 9 Hz, 2H, H2′, H6′), 7.69 (ddd, J1 = 8.5,
J2 = 8.7, J3 = 1.7 Hz, 1H, H7), 7.54 (dd, J1 = 8.4 Hz, 1H, H8), 7.41 (ddd, J1 = 8.0, J2 = 8.0, J3 = 1.0 Hz, 1H,
H6), 7.02 (dd, J1 = 9 Hz, 2H, H3′, H5′), 6.73 (s, 1H, H3), 3.87 (s, 3H, H11). 13C NMR (100 MHz, CDCl3)
δ: 178.4 (s, C4), 163.5 (s, C2), 162.5 (s, C4′), 156.3 (s, C9), 133.6 (d, C7), 128.1 (d, C2′, C6′), 125.7 (d, C5),
125.1 (d, C6), 124.1 (s, C10), 124.0 (s, C1′), 118.0 (d, C8), 114.5 (d, C3′, C5′), 106.3 (d, C3), 55.6 (q, C11).
GC-MS m/z (rel. int.) = 252.18 [M]+ (6), 209.14 (4), 181.09 (2), 132.11 (13), 117.09 (11), 92.05 (64), 89.07
(51), 76.05 (24), 63.07 (100).
2-(3-methoxyphenyl)-4H-chromen-4-one (3f): white powder (yield 49%). C16H12O3. Mp = 118–120 ◦C.
IR (ATR diamond, cm−1) = 3036 (C-H), 2844 (C-H), 1639 (C=O), 1130 (C-O) cm−1. 1H NMR (400 MHz,
CDCl3) δ: 8.24 (dd, J1 = 8.0, J2 = 1.2 Hz, 1H, H5), 7.71 (ddd, J1 = 8.4, J2 = 8.8, J3 = 1.6 Hz, 1H, H5′), 7.57
(dd, J1 = 8.8 Hz, 1H, H8), 7.52 (ddd, J1 = 8.8, J2 = 8.8, J3 = 1.2 Hz, 1H, H7), 7.44 (ddd, J1 = 8.0, J2 = 2.8,
J3 = 2.0 Hz, 2H, H2′, H6′), 7.42 (dd, J1 = 8.0, J2 = 2.8 Hz, 1H, H4′), 7.08 (ddd, J1 = 8.4, J2 = 8.0, J3 = 1.0
Hz, 1H, H6), 6.83 (s, 1H, H3), 3.89 (s, 3H, H11). 13C NMR (100 MHz, CDCl3) δ: 178.6 (s, C4), 163.3
(s, C2), 160.1 (s, C3′), 156.3 (s, C9), 133.9 (d, C7), 133.2 (s, C1′), 130.2 (d, C5′), 125.8 (d, C5), 125.3 (s,
C10), 124.1 (d, C6), 118.8 (d, C6′), 118.2 (d, C8), 117.3 (d, C4′), 111.9 (d, C2′), 107.9 (d, C3), 55.6 (q, C11).
GC-MS m/z (rel. int.) = 252.25 [M]+ (32), 251.23 (6), 224.24 (13), 152.19 (12), 132.18 (81), 120.14 (44),
102.17 (63), 92.13 (100).
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2-(3,4-dimethoxyphenyl)-4H-chromen-4-one (3g): white powder (yield 85%). C17H14O4. Mp =
128–130 ◦C. IR (ATR diamond, cm−1) = 3062 (C-H), 2929 (C-H), 1651 (C=O), 1144 (C-O) cm−1. 1H NMR
(400 MHz, CDCl3) δ: 8.23 (dd, J1 = 7.9, J2 = 1.5 Hz, 1H, H5), 7.70 (ddd, J1 = 8.5, J2 = 8.6, J3 = 1.7 Hz,
1H, H7), 7.57 (dd, J1 = 8.4, J2 = 1.9 Hz, 2H, H8, H2′), 7.42 (ddd, J1 = 8.0, J2 = 7.6, J3 = 1.0 Hz, 1H, H6),
7.39 (ddd, 1H, H6′), 6.99 (d, 1H, H3′), 6.77 (s, 1H, H3), 3.98 (s, 3H, H11), 3.96 (s, 3H, H12). 13C NMR
(100 MHz, CDCl3) δ: 193.7 (s, C4), 163.6 (s, C2), 151.9 (s, C9), 149.4 (s, C5′), 145.7 (s, C4′), 136.2 (d, C7),
129.6 (d, C5), 127.7 (s, C10), 123.6 (d, C6), 121.6 (s, C1′), 120.2 (d, C2′), 118.8 (d, C8), 117.9 (d, C3′), 111.3
(d, C6′), 110.5 (d, C3), 56.1 (q, C11, C12). GC-MS m/z (rel. int.) = 282.18 [M]+ (35), 168.13 (12), 147.11
(16), 127.18 (25), 121.08 (100), 119.05 (32), 92.07 (86), 91.09 (99), 76.08 (91).
2-(4-chlorophenyl)-4H-chromen-4-one (3h): white powder (yield 82%). C15H9ClO2. Mp = 188–190 ◦C.
IR (ATR diamond, cm−1) = 3071 (C-H), 1647 (C=O), 756 (C-Cl) cm−1. 1H NMR (400 MHz, CDCl3) δ:
8.23 (dd, J1 = 7.9, J2 = 1.4 Hz, 1H, H5), 7.86 (dd, J1 = 8.8 Hz, 2H, H3′, H5′), 7.71 (ddd, J1 = 8.5, J2 = 8.7,
J3 = 1.7 Hz, 1H, H7), 7.55 (dd, J1 = 8.4, J2 = 1.0 Hz, 1H, H8), 7.50 (dd, J1 = 8.8 Hz, 2H, H2′, H6′), 7.43
(ddd, J1 = 8.0, J2 = 7.8, J3 = 1.0 Hz, 1H, H6), 6.77 (s, 1H, H3). 13C NMR (100 MHz, CDCl3) δ: 178.2 (s,
C4), 162.3 (s, C2), 156.2 (s, C9), 138.0 (d, C7), 134.0 (s, C4′), 130.3 (d, C2′, C6′), 129.4 (d, C3′, C5′), 127.6
(s, C1′), 125.8 (d, C5), 125.4 (s, C10), 124.0 (d, C6), 118.1 (d, C8), 107.8 (d, C3). GC-MS m/z (rel. int.) =
258.18 [M]+ (3), 256.18 (10), 228.16 (6), 165.18 (3), 136.13 (13), 120.12 (29), 101.13 (28), 92.11 (100).
2-(4-(dimethylamino)phenyl)-4H-chromen-4-one (3i): white powder (yield 67%). C17H15NO2. Mp =
193–195 ◦C. IR (ATR diamond, cm−1) = 3057 (C-H), 1659 (C=O), 1277 (C-N) cm−1. 1H NMR (400 MHz,
CDCl3) δ: 8.17 (dd, J1 = 8.8, J2 = 2 Hz, 1H, H5), 8.04-7.78 (m, 3H, H6, H7, H8), 7.77 (dd, 2H, H3′, H5′),
6.94 (dd, 2H, H2′, H6′), 6.84 (s, 1H, H3), 2.99 (s, 6H, H11). 13C NMR (100 MHz, CDCl3) δ: 176.63 (s,
C4), 162.4 (s, C2), 155.4 (s, C9), 152.5 (s, C4′), 135.7 (d, C7), 133.8 (d, C2′), 133.5 (d, C6′), 133.1 (d, C5),
125.2 (s, C10), 124.6 (d, C6), 118.2 (s, C1′), 117.9 (d, C8), 116.7 (d, C3′), 103.9 (d, C3). GC-MS m/z (rel.
int.) = 265.26 [M]+ (10), 261.68 (1), 195.10 (2), 104.19 (10), 90.71 (9), 74.87 (11), 73.05 (100).
2-(anthracen-9-yl)-4H-chromen-4-one (3j): yellow powder (yield 84%). C23H14O2. Mp = 193–195 ◦C.
IR (ATR diamond, cm−1) = 3063 (C-H), 1643 (C=O), 1122 (C-O) cm−1. 1H NMR (400 MHz, CDCl3) δ:
8.62 (s, 1H, H8′), 8.40 (dd, J1 = 7.96, J2 = 1.6 Hz, 1H, H5), 8.08 (dd, J1 = 6.7, J2 = 1.5 Hz, 2H, H3′, H6′),
7.97 (dd, J1 = 7.9, J2 = 1.9 Hz, 2H, H10′, H13′), 7.73 (ddd, J1 = 8.5, J2 = 8.6, J3 = 1.6 Hz, 1H, H7), 7.53-7.47
(m, 6H, H6, H8, H4′, H5′, H11′, H12′), 6.69 (s, 1H, H3). 13C NMR (100 MHz, CDCl3) δ: 178.1 (s, C4),
163.8 (s, C2), 157.4 (s, C9), 144.0 (d, C7), 134.0 (s, C1′), 131.1 (s, C7′, C9′), 130.2 (d, C6′, C10′), 130.0 (d,
C5), 128.8 (s, C2′, C14′), 127.3 (d, C3′, C13′), 126.1 (d, C4′, C12′), 125.7 (d, C5′, C11′), 125.6 (s, C10),
125.0 (d, C6), 124.3 (d, C8′), 118.5 (d, C8), 116.3 (d, C3). GC-MS m/z (rel. int.) = 322.27 [M]+ (7), 321.25
(4), 305.25 (9), 202.15 (19), 200.16 (9), 189.11 (2), 120.06 (15), 92.08 (100).
2-(furan-2-yl)-4H-chromen-4-one (3k): brown yellow powder (yield 45%). C13H8O3. Mp = 118–120 ◦C.
IR (ATR diamond, cm−1) = 3105 (C-H), 1651 (C=O), 1054 (C-O) cm−1. 1H NMR (400 MHz, CDCl3) δ:
8.21 (dd, J1 = 7.9, J2 = 1.5 Hz, 1H, H5), 7.68 (ddd, J1 = 8.5, J2 = 8.7, J3 = 1.6 Hz, 1H, H7), 7.62 (dd, J1 = 2.3,
J2 = 1.6 Hz, 1H, H4′), 7.49 (dd, J1 = 8.4, J2 = 1.0 Hz, 1H, H8), 7.41 (ddd, J1 = 8.0, J2 = 8.0, J3 = 1.0 Hz, 1H,
H6), 7.13 (d, 1H, H2′), 6.72 (s, 1H, H3), 6.60 (dd, J1 = 3.5, J2 = 1.7 Hz, 1H, H3′). 13C NMR (100 MHz,
CDCl3) δ: 177.8 (s, C4), 155.9 (s, C2), 155.2 (s, C9), 146.5 (s, C1′), 145.9 (d, C4′), 133.8 (d, C7), 125.8 (d,
C5), 125.2 (s, C10), 124.3 (d, C6), 117.9 (d, C8), 113.1 (d, C3′), 112.6 (d, C3), 105.6 (d, C2′). GC-MS m/z
(rel. int.) = 212.12 [M]+ (11), 184.12 (7),156.12 (2), 128.12 (9), 120.07 (24), 92.07 (100), 63.07 (94).
2.4. In Vitro Antioxidant Activity assay
2.4.1. DPPH Radical-Scavenging Assay
The radical-scavenging activity was performed, as described by Salazar-Aranda et al. [26], with
slight modifications. Different concentrations of the sample were prepared with methanol by serial
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dilutions. An aliquot of each dilution (0.5 mL) was mixed with 0.5 mL of a methanolic solution
of 1,1-diphenyl-2-picrylhydrazyl (DPPH) (7.5 mg/250 mL). The mixtures were incubated at room
temperature in the dark for 30 min. Using methanol as a blank, the spectrophotometric measurement
was performed at 517 nm (A517). The radical-scavenging activity was calculated as a percentage of
DPPH decoloration using the following formula:
DPPH (%) = [1 − (B/A)] × 100 (1)
Where A represents the A value of the control (DPPH solution) and B represents the sample.
All of the determinations were performed in triplicate. For each compound, the percentage of DPPH
decoloration was plotted against the concentration of each dilution. The concentration that is required
to decrease the absorbance of DPPH by 50% was obtained by interpolation, from a linear regression
analysis, and expresses the EC50 value. Quercetin was used as a reference compound.
2.4.2. ABTS (2-2′-azino-bis-(3-ethylbenzothiazoline-6-sulfonate)) Radical-Scavenging Assay
ABTS radical cation (ABTS+) scavenging assay was determined using the methodology developed
by Re et al. and Kuskoski et al. [27,28] with slight modifications. ABTS was dissolved in water at
7 mM concentration. ABTS radical cation (ABTS+) was produced by reacting ABTS stock solution with
2.45 mM potassium persulfate and then the mixture was kept in the dark at room temperature for
16-18 h before use. The ABTS+ solution (150 µL) was diluted with methanol to obtain an absorbance at
0.7 ± 0.02, which is taken as initial absorbance. Of this solution, 980 µL was added to 20 µL of different
concentrations of the sample. The mixture was stirred, incubated at room temperature for 30 min, and
read at a wavelength of 754 nm, which was taken as the final absorbance. The results are shown as a
percentage of inhibition using the following formula:
% of inhibition = [(A1 − A2)/A1] × 100 (2)
Where A1 is the initial absorbance of the ABTS solution and A2 is the final absorbance of the
ABTS solution in the presence of the sample. All of the determinations were performed in triplicate.
For each compound, the percentage of inhibition was plotted against the concentration of each
dilution. The concentration required to decrease the absorbance of ABTS by 50% was obtained by
interpolation, from a linear regression analysis, and expresses the EC50 value. Quercetin was used as a
reference compound.
2.4.3. β-Carotene/linoleic Acid bleaching Assay
Heat-induced oxidation of an aqueous emulsion system of β-carotene and linoleic acid was
used for testing the antioxidant activity that was described by Burda and Oleszek [29], with slight
modifications. To 1 mL of β-carotene solution (0.2 mg/mL in chloroform) was added 20 µL linoleic
acid and 200 µL of Tween 20. Once the chloroform was evaporated, 50 mL of distilled water saturated
for 1 h with oxygen was added. An amount of 2.5 mL of the β-carotene emulsion was mixed with
0.35 mL of the corresponding compound solution in methanol (0.5 mg/mL) and the resulting mixture
was shaken. The absorbance of the samples was measured on a spectrometer at 470 nm immediately
after their preparation (t = 0 min), and at the end of the experiment (t = 120 min), during this time the
samples were kept at 50 ◦C. The antioxidant activity (AA) was expressed as percentage of inhibition of
β-carotene bleaching, as compared to the control, and calculated using the following formula:
AA (%) = {1 − [(AS0 − AS120)/(AC0 − AC120)]} × 100 (3)
Where As0 is the absorbance of the sample at 0 min, As120 is the absorbance of the sample at
120 min, Ac0 is the absorbance of the control sample at 0 min, and Ac120 is the absorbance of the control
sample at 120 min. α-tocopherol was used as a reference compound.
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2.5. In Vitro Acetylcholinesterase Inhibitory Assay
Acetylcholinesterase activity was determined with the methodology that was reported by
Adewusi (2011) [30]. In a 96-well plate was added 75 µL of Trizma-HCl buffer (50 mM, pH 8) and 75 µL
of synthesized compound and serial dilutions were made (final well concentrations were between 150
and 2.4 µg/mL in the buffer, and DMSO at a final maximum concentration of 0.15%). Afterwards, to
each well was added 25 µL of a buffer solution of ATCl 15 mM (final concentration of 1.5 mM) and
125 µL of a buffer solution of DTNB 3 mM (final concentration 1.5 mM). Absorbance was measured in
a microplate reader (Multiskan FC, Thermo Scientific) at 405 nm every 45 s in three consecutive times.
After that, to each well was added 25 µL of an acetylcholinesterase enzyme buffer solution at 2 U/mL
enriched with bovine serum albumin 0.1 mg/mL (final well enzyme concentration 0.2 U/mL) and the
absorbance was measured five consecutive times every 45 s. Six wells of each plate were employed
without a compound to test, to serve as a 100% enzymatic activity control. The increase of absorbance
due to spontaneous substrate hydrolysis was corrected subtracting the absorbance before the enzyme
addition from the absorbance that was obtained after the enzyme addition. Inhibition percentage was
calculated by the following equation
inhibition % = 1 − (Asample/Acontrol) × 100 (4)
Where Asample is the absorbance difference between time 0 and 225 s in presence of any compound
to test or inhibitor, and Acontrol is the absorbance difference between time 0 and 225 s of the 100%
enzymatic activity control. Inhibitory concentration 50 (IC50) was calculated by interpolation from the
graphic of inhibition percentages in function of the employed concentrations. All of the experiments
were performed by triplicate and galantamine was employed as a positive control, which is a drug
that is currently used for Alzheimer disease treatment. [12]
2.6. Molecular Docking
The three-dimensional structures of the ligands were generated with UCSF Chimera 1.11.2 [31]
through their SMILES string. The structures were energy-minimized using Chimera default parameters
(which include MMTK, Amber, and Amber’s Antechamber parameters) [32]. Rotatable bonds and
atomic charges from the ligands were defined with AutoDock Tools 1.5.6. [33]. The crystallographic
structure of the AChE receptor (PDB ID:1EVE) in complex with donepezil was downloaded from the
Protein Data Bank (https://www.rcsb.org/). The preparation for the receptor with AutoDock Tools
included remotion of the co-crystalized ligand and water molecules, hydrogen addition and charges
calculation. For the docking, AutoDock Vina [34] was employed, with a grid box of 30 × 30 × 30 Å
with center coordinates x = 2.27731, y = 63.7499 and z = 65.4998. Five docking runs with 10 poses each
were made per ligand, with an exhaustiveness of 8. Visualizations of the docked poses for their analysis
were made with Chimera. To validate the docking protocol, a re-docking of co-crystallized donepezil
was made and the resulting pose was compared to the crystallographic one through their RMSD.
3. Results and Discussion
3.1. Synthesis of Chalcone and Flavone Analogs (2a–2k, 3a–3k)
Chalcones are usually synthesized by condensation reactions with acid or basic catalysis, even
though recently a great number of new procedures for the synthesis of these molecules due to the
great interest on their biological properties have appeared. Claisen–Schmidt reaction with basic
conditions is the most widely synthesis reported in the literature, because of the easily process and
efficiency in the product formation [35]. The substituted 2-hydroxychalcones 2a–2k were prepared
by the Claisen–Schmidt condensation of the respective substituted benzaldehyde 1a–1k (1 eq) and
2-hydroxyacetophenone (1 eq) in the presence of NaOH in ethanol/water at room temperature
by the known literature method (Scheme 1) [36]. This methodology allowed for the obtention of
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eleven compounds with moderate to high yields, between 40–97%, being the highest one the yield
for compound 2h. The oxidative cyclization of 2-hydroxychalcones 2a–2k to flavones 3a–3k was
performed using the classical iodine (1 mmol) in DMSO (Scheme 1) system. This method is particularly
useful in flavone synthesis starting from 2-hydroxychalcones as it has been observed the iodine does
not give secondary reactions despite the high temperature employed [37]. The corresponding flavones
were successfully synthesized with yields between 40–85%.
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Scheme 1. Reaction Conditions: (i) NaOH 50%/ethanol-H2O, room temperature, 12 h. (ii) I2 – DMSO,
reflux 130 ◦C, 30 min.
All of the compounds were characterized by IR, 1H, and 13C-NMR and mass spectroscopy; in
the 1H NMR spectra of the compounds 2a–k can be noticed the hydroxyl proton in ring A between
δ 12.63–13.18 ppm, due to the intramolecular hydrogen bond made with the carbonyl oxygen atom.
The vinylic protons of the α,β-unsaturated system are present as doublets for Hα = 7.48–8.10 ppm and
Hβ =7.69–8.89 ppm, being the coupling constants JHα-JHβ = 14.9–15.8 Hz, which indicates a trans
configuration for these protons. All of the aromatic protons were observed at their expected shifts, so
as their coupling constants. In 13C-NMR spectra, the carbonyl carbon is observed at δ 193.3–193.8 ppm,
being the α- and β- carbons at 117.7–121.7 ppm and 129.7–145.8 ppm, respectively.
For the flavone type compounds 3a–k, carbonyl α-proton H-3 is observed as a singlet with
shifts of 6.69–7.12 ppm, the aromatic protons of the A and B rings were at their expected shifts and
coupling constants. Regarding 13C-NMR, the carbonyl carbon shifts to a lower frequency with δ
177.0–193.7 ppm, being the carbons C-2 and C-3 identified at 155.9–163.9 ppm and 104.5–116.3 ppm,
respectively. The assignments were made by HSQC and HMBC experiments.
NMR spectra, including bidimensional ones, of selected chalcones and flavones can be observed
in Figures S1–S24 in the supplementary materials.
3.2. Antioxidant Activity
To determine antioxidant activities of 2-hydroxychalcones 2a–2k and flavone analogs 3a–3k,
heat-induced oxidation in a β-carotene and linoleic acid system, DPPH radical scavenging activity and
ABTS radical cation decolorization assay were evaluated. The EC50 values of compounds, quercetin
and α-tocopherol obtained are shown in Table 1 and Figure 2.
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Table 1. Antioxidant activity of synthesized compounds 2a–2k and 3a–3k.
Compound
B-Ring Substituent Scavenging Activity (EC50, µg/mL)
R1 R2 R3 R4 ABTS (2-2
′-azino-bis-(3-ethylbenzothiazoline-
6-sulfonate)) DPPH
2a 1.61 × 104 ± 5.73 × 10−3 260 ± 1.17 × 10−2
2b OH 21 ± 7.07 × 10−5 8 ± 1.24 × 10−4
2c OMe OH 164 ± 4.95 × 10−4 19 ± 1.18 × 10−3
2d OH NO2 564 ± 4.24 × 10−4 23 ± 9.76 × 10−4
2e OMe 341 ± 2.83 × 10−4 100 ± 2.57 × 10−3
2f OMe 487 ± 6.93 × 10−3 170 ± 4.10 × 10−3
2g OMe OMe 1.14 × 10−2 ± 7.42 × 10−7 5 × 104 ± 7.76 × 10−1
2h Cl 5.23 × 103 ± 9.90 × 10−4 15 ± 7.43 × 10−4
2i N(CH3)2 6.96 × 10−2 ± 2.12 × 10−7 9.3 ± 4.95 × 10−5
2j Anthracene 548 ± 3.54 × 10−3 1.7 ± 6.82 × 10−5
2k Furan 79 ± 6.36 × 10−4 5.4 × 10−3 ± 6.50 × 10−8
3a 2.53 × 104 ± 4.24 × 10−3 170 ± 1.94 × 10−5
3b OH 0.3 ± 3.54 × 10−5 0.1 ± 1.39 × 10−6
3c OMe OH 497 ± 1.98 × 10−4 9 ± 4.60 × 10−5
3d OH NO2 155 ± 1.11 × 10−3 6.2 ± 1.52 × 10−4
3e OMe 3.00 × 103 ± 1.21 × 10−3 30 ± 3.61 × 10−3
3f OMe 112 ± 2.90 × 10−4 39 ± 1.58 × 10−3
3g OMe OMe 861 ± 2.55 × 10−4 410 ± 6.85 × 10−3
3h Cl 2.6 × 103 ± 1.06 × 10−3 7.4 ± 1.09 × 10−5
3i N(CH3)2 1.9 × 10−3 ± 6.51 × 10−8 0.25 ± 2.14 × 10−5
3j Anthracene 1.07 × 105 ± 3.99 × 10−4 1 × 10−8 ± 1.61 × 10−12
3k Furan 1.26 × 103 ± 7.78 × 10−4 0.1 ± 7.85 × 10−6
*Quercetin 50 ± 4.1 × 10−4 3 ± 2 × 10−4
* Served as reference compound. Values are mean ± SD, n = 2.
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The results showed that most of the compounds exhibited high activity with DPPH and
β-carotene ssay and weak activity in ABTS; additionally, the flavone-typ derivatives showed a better
tiradical and antioxidant activity as compared to their cha cone precursors. Structure-antiox dan
activity relationships of chalcones and fl vones suggest this activity is related to a series of different
mechanisms, like free radic l neutralization, hydrogen donati , singlet oxygen quenching, and metal
chelation [38].
The high double bond conjugation of chalcone and flavonoid systems, just as the prese ce of a
C2-C3 double bond and a carbonyl i C-4 position, have been reported as s ructural characteristics for the
antioxidant activity [39], being these incorporated i the basic skel ton of all the synthesized compo nds.
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Bearing this in mind, molecules 2a and 3a have no substituents in their structures, having the
lowest activity of all the generated analogs, therefore it is possible to infer that the addition of at least
one substitution favors the antioxidant potential.
In chalcone type molecules, the antioxidant properties are vastly influenced by the two aryl groups
and their substitution patterns. The presence of hydroxyl groups to improve the antioxidant activity
due to its easy conversion to phenoxy radicals by the hydrogen transfer mechanism is considered to be
indispensable [40].
Hydroxyl group presence was evaluated in the 2b (o-OH), 2c (p-OH, m-OMe), and 2d (o-OH,
m-NO2) analogs; despite that the three had great activity in the tested techniques (see Table 1), 2b
showed better results when compared to the other analogs in the antiradical techniques DPPH and
ABTS, with an EC50 of 8 µg/mL and 21 µg/mL respectively, surpassing quercetin as the control used
in ABTS (EC50 of 50 µg/mL). This indicates that in the radical reduction mechanism by hydrogen
donation (like DPPH and ABTS), the addition of other substitutions different from hydroxyl groups
diminishes activity, especially using electron-attractor groups as NO2 [41]. A similar behavior is
appreciated in the results of flavones 3b, 3c, and 3d, with 3b showing good activity with an EC50 of
0.1 µg/mL in DPPH and 0.3 µg/mL in ABTS, in both situations surpassing the positive control; again,
it was observed that the presence of electron-attractor groups lowers the activity. Analogs 2h and 3h
with p-Cl substitutions did not show considerable activity when compared to the controls.
The influence of electron-donor groups, like methoxyl, can be analyzed with the 2e (p-OMe), 2f
(m-OMe), and 2g (p,m-OMe) analogs; the presence of these groups did not favor the activity, getting
concentrations of 100, 170, and 5 × 104 µg/mL, respectively, in DPPH assay, having a similar behavior
of the flavones 3e–g, with EC50 of 30, 39, and 410 µg/mL. These results may appear to contrast with
the reported by many authors where methoxyl groups are considered an important factor for the
antioxidant activity [42,43], however, this is the case where methoxyl groups help with the lipophilicity
of the molecule, for example, when the antioxidant activity is measured by the lipid peroxidation
activity assay [39]. When employing DPPH test, the transfer of acid protons is required; this implies
that just as in the case of the chalcones, we consider indispensable the presence of at least one hydroxyl
group, explaining the lack of scavenging activity for the synthesized compounds with only methoxyl
groups (3e–g).
Molecules 2i–3i, both with p-dimethylamino substituent showed excellent results with an
EC50 of 9.3 and 0.25 µg/mL, respectively, in the DPPH assay, having an EC50 of 6.9 × 10−2 and
1.9 × 10−3 µg/mL in ABTS; substituents that increase the electronic density, like dimethylamine
groups, show potent antioxidant activity that is attributed to the resonance effect involving the pair of
electrons of the heteroatom [44].
The β-carotene decolorization assay brings an outlook to the capacity of an antioxidant to
inhibit the lipid peroxidation initiated by the hydrogen abstraction or addition of oxygen radical [45].
The chalcones 2c and 2d with hydroxyl substitution showed good activity in this technique with
percentages of activity between 76–84%, while the flavones with the same substitution showed results
between 67–77%. Undoubtedly, the presence of methoxyl groups in the analogs B ring favored the
antioxidant activity, the chalcones 2e and 2f exhibit 99% of antioxidant activity, while the flavones 3e,
3f, and 3g present results of 82, 99 and 84% respectively, all of them better than α-tocopherol (60%).
This allows for determining that the presence of electron-donor groups in the B ring benefits this
activity [46,47].
From all the synthesized analogs, it is important to highlight the results obtained for 2j, 2k, 3j,
and 3k, which have anthracene and furan substitutions, while they presented antiradical activity at
very low concentrations in the DPPH assay, with EC50 of 1.7 and 5.4 × 10−3 µg/mL for 2j and 2k, and
1 × 10−8 and 0.1 µg/mL for 3j and 3k, being far better than the control quercetin (3 µg/mL).
These same four molecules showed a high antioxidant activity in the β-carotene technique, with
results of 98% and 88% for the 2j and 2k chalcones, while the 3j and 3k flavones had 99% and 85%,
respectively, surpassing the 60% antioxidant activity of α-tocopherol. It is known that the oxidation
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of polycyclic aromatic hydrocarbons, such as anthracene generates anthraquinone type products,
with 9,10-anthraquinone and 9-hydroxyanthrone being the more abundant [48], the basic skeleton
for anthraquinones and anthrone, which provides them the capacity to act as electron acceptors
(electrophiles); furthermore, their high conjugation gives them great stability (by resonance means),
potentiating the antioxidant activity [49,50]. On other hand, the oxidation of furans gives as a result
oxyfuranones in the case of monosubstitutions, or diketones in the case of 2,5-disubstituted furans [51];
Y. Sugiyama et al. reported the importance of diketonic systems in the antioxidant activity, both in
their keto or enol form [52].
3.3. Acetylcholinesterase Inhibitory Assay
The acetylcholinesterase inhibitory activity of the synthesized compounds was evaluated
employing Adewusi adaptation of Ellmans spectrophotometrical assay [30], using galantamine
as a reference. The results for these experiments are shown with their IC50 values on Table 2.
The compounds that were chosen for screening can be divided into two groups based on their
structural features: chalcones and flavones.
Table 2. Acetylcholinesterase inhibitory activity of synthesized compounds 2a–2k and 3a–3k.
Compound IC50 (µg/mL) Compound IC50 (µg/mL)
2a > 150 3a > 150
2b > 150 3b 61.2 ± 1.39
2c 52.7 ± 11.98 3c 78.4 ± 1.92
2d 21.5 ± 2.61 3d 26.8 ± 5.91
2e > 150 3e 43.5 ± 4.31
2f > 150 3f 60 ± 9.96
2g > 150 3g 43.5 ± 2.52
2h > 150 3h > 150
2i 80.4 ± 5.97 3i > 150
2j > 150 3j 77.6 ± 31.89
2k 66.4 ± 6.15 3k > 150
*Galantamine 0.574 ± 0.07
* Served as reference compound. Values are mean ± SD, n = 3.
Chalcones are 1,3-diphenyl-2-propene-1-one systems, in which two aromatic rings are linked
by a three carbon α, β-unsaturated carbonyl system. The compounds with this backbone have been
reported to possess various biological activities [53]. The IC50 values of these compounds are listed in
Table 2. Hasan et al. [54] reported that hydroxyl groups in ortho position of the A ring of chalcones,
are an important structural element in the AChE inhibitory activity; however, in our study all the
synthesized chalcones had the o-OH substitution in their A ring, and most of them displayed no
inhibition effect in the tested concentration scale. Compounds 2c, 2i, and 2k showed an inhibitory
effect with IC50 values of 52.7, 80.4, and 66.4 µg/mL, respectively, in contrast to the rest of molecules
that presented results above 150 µg/mL.
On the other hand, results of the flavone group 3a–3k that are based upon a fifteen-carbon skeleton
consisting of two benzene rings (A and B) linked via a heterocyclic pyrane ring (C) (Figure 1) indicate
that they were more active than the chalcone group. Only the compounds 3a, 3h, 3i, and 3k presented
poor inhibition as compared to the rest of flavones that, in the majority, have hydroxyl or methoxyl
groups in their B ring, where compounds 3e, 3g, 3f, and 3b outstand with an IC50 of 43.5, 43.5, 60.0,
and 61.2 µg/mL, respectively; however, compound 3d with o-OH, m-NO2 in the B ring was found to
be the best flavone inhibitor of AChE, having an IC50 of 26.8 µg/mL.
It has been acknowledged that hydroxyl and methoxyl groups in the A and B rings of flavones are
deeply related to bioactivity and their capacity to protein bonding, being the hydroxyl groups that are
favorable for the flavonoids interaction with acetylcholinesterase by hydrogen bonds formation in the
enzyme peripheral anionic site (PAS) [55], which would explain the activity showed by compounds 3b,
Appl. Sci. 2019, 9, 410 14 of 20
3c, and 3d (61.2, 78.4, and 26.8 µg/mL). On other hand, the presence of methoxyl groups in flavonoids
favors the inhibition effect due to the interaction with residue Trp279, located in the entrance to the
active site (in the PAS), this could explain the results obtained for analogs 3e–3g.
While we can notice a general improvement of the results with the presence of hydroxyl and
methoxyl groups in the chalcones B ring, Sukumaran et al. [56] mentions that, in 2′-hydroxychalcones,
the AChE inhibition is generally favored with halogens in the B ring. Nevertheless, their chalcone with
chlorine in p-position of the B ring did not showed significant activity, molecule that corresponds with
our compound 2h, from which we neither detect activity in the tested concentration scale.
As can be noticed, chalcone 2d and flavone 3d, both with o-OH and m-NO2 substitutions, were
the most active compounds with IC50 values of 21.5 and 26.8 µg/mL, respectively, these results suggest
that the presence of the nitro group in both molecules enhances the inhibitory activity; it has been
previously reported that the introduction of basic or permanently charged nitrogen atoms and aromatic
systems, are common structural characteristics in molecules for their interaction with the binding sites
of acetylcholinesterase [57].
3.4. Molecular Docking Analysis
For the molecular docking studies, the compounds with the best in vitro results 2d and 3d
were selected in order to gain insight of their interactions with the AChE receptor and explain
their biological results. AutoDock Vina was selected to perform the in silico analysis, using the
crystallographic structure of the Pacific electric ray Torpedo californica AChE (TcAChE) available from
Protein Data Bank (PDB ID:1EVE) as its similarity with human AChE allows for employing it in
docking studies [58]. Having selected 1EVE, a docking grid was generated in the active site region
defined by the co-crystallized receptor’s ligand donepezil. To assure effectiveness of the analysis,
it was necessary to validate the method; for this, a re-docking of the co-crystallized donepezil was
realized with the same parameters intended to use for our ligands. We compared the best result pose
for donepezil with the co-crystallized one obtaining a RMSD of 1.1, which, being lower than 1.5–2 Å,
is considered to be a successful analysis, suitable for predicting ligand poses [59].
In Table 3, the resulting scores of the docking for compounds 2d and 3d with the inhibition
constants can be observed, which AutoDock calculates by the formula:
Ki = exp(∆G × 1000 Rcal × TK ) (5)
∆G is the docking binding energy, Rcal value is 1.98719, and TK value is 298.15. In the in vitro results,
chalcone 2d was the most active synthesized compound with an IC50 of 21.5 µg/mL, followed by the
flavone 3d (26.8 µg/mL); accordingly, the docking gave a better score for 2d (−10.2 kcal/mol) against
3d (−9.78 kcal/mol). The more negative the docking score (binding energy value), the better affinity
the ligand has for the receptor.
Table 3. Docking scores for compounds 2d and 3d.
Compound Binding Energy(kcal/mol)
Inhibition Constant
(nM)
Principal Residues
Interactions
2d −10.2 33.37 Trp84, Tyr334, Tyr130
3d −9.78 67.79 Trp84, Tyr334, Tyr130
Analysis of the poses generated showed us that our compounds interact with AChE mostly by
pi-pi interactions with the active site residues.
The active site of AChE consists in a cavity or gorge in the receptor surface that is approximately
20 Å deep; besides the catalytic triad of the enzyme (Ser200, His440, and Glu327), which is located at
the bottom of the gorge, several residues have been identified as important zones for the interaction
of ligands, such as Trp84, Phe330, Glu199, and Gly441 that make the central anionic site (CAS), and
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Trp279, Tyr334, Tyr121, and Tyr70 at the peripheral anionic site (PAS) [60,61]. Both 2d and 3d poses are
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one oxygen of the nitro group is near the hydrogen of Tyr130, at only 2.7 Å, the angle between them
does not allow a proper hydrogen bond. A small turn of the nitro or hydroxyl groups would be needed
for this to happen, but a weak interaction between them might be helping the interaction of 2d with
this residue. The clearer interactions for 2d appear with Trp84, a residue that has been reported as
an important one for ligand interactions (especially with quaternary groups from acetylcholine and
other compounds) [58,62]. In this case, Trp84 is near the positively charged nitrogen of the nitro group,
although its position appears to be almost over the B ring of the chalcone, allowing for pi-pi stacking at
3.7 Å. Another pi-pi stacking can be observed between the A ring of 2d and Tyr334 in the PAS region,
with 4 Å among the aromatic rings (Figure 4). The side of chalcone 2d with the A ring rests in the
mostly hydrophobic zone created by Trp334, Phe331, and Phe330, while the side of the B ring points to
a less hydrophobic area.
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The case for the best generated pose of flavone 3d is very similar to its chalcone counterpart.
Although a formal hydrogen bond is not detected by the Chimera software due to the angle between
them, one oxygen of the nitro group is near the hydrogen of Tyr130, at 2.6 Å, so a weak interaction
among these atoms could be possible (Figure 5). The nitro group is near to Trp84, but the B ring
appears to have a better interaction with this residue in form of pi-pi stacking at a distance of 4 Å. The A
ring has proximity to Tyr334, even though with the new ring formation the flavone 3d has a more rigid
position for the A ring, which now appears to have with its edge a perpendicular pi-pi interaction with
Tyr334 at 3.6 Å. The C ring is oriented to Phe330 with a distance among them of 4.4 Å. As the chalcone
2d did, the B ring with the nitro group of the flavone 3d is oriented to the bottom of the gorge, in a less
hydrophobic area, while the rest of the structure is towards the hydrophobic zone of Trp334, Phe331,
and Phe330, as can be seen in Figure 6.Appl. Sci. 2019, 9, x FOR PEER REVIEW 16 of 21 
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4. Conclusions
In conclusion, for the three analyzed techniques, the flavone type analogs showed a better
antioxidant profile when compared to the chalcones, however this does not mean that the latter were
inactive since many of them resulted highly active. Surprisingly, the compounds 2j, 2k, 3j, and 3k
presented a high potential as antioxidant agents, this could be due to the quinone and oxyfuranone
type products that are generated after their oxidation. As previous reports have stated, the presence of
hydroxyl groups favors the antiradical activity mediated by hydrogen donation, as it could be noticed
that compounds 2b and 3b surpassed the positive controls in both DPPH and ABTS assays; in the
β-carotene technique, the electron-donor substitutions were the most active.
On the other hand, in the AChE inhibition assay, the better results from the chalcone and flavone
families (compounds 2d and 3d) share the nitro functional group, with IC50 values of 21.5 and
26.8 µg/mL, respectively. The docking results suggest that the principal interactions compounds 2d
and 3d have with AChE active site are mostly pi-pi stackings. This can be observed with residues Trp84
and Tyr334 from the CAS and PAS, which are known binding zones of the enzyme.
Although further in vivo testing must be performed, our results represent an important step
towards the identification of improved antioxidants and acetylcholinesterase inhibitors.
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